Program
lorundrostat hydrobromide
Also written as “MLS101 psilocybin”, “MLS-101 (Part I)” and “MLS-101 (Part II)”.
Its studies are mostly in Premenstrual Dysphoric Disorder, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mineralys Therapeutics | 10 open or running | phase 2since Jul 20, 2021 | Jul 20, 2021 | none ahead |
| MycoMedica Life Sciences PBC | 11 open or running | phase 1since Aug 25, 2026 | Aug 25, 2026 | Sep 2027phase 1 · NCT07818720 |
| Tanabe Pharma | 10 open or running | phase 1since Oct 31, 2016 | Oct 31, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2016First study: phase 1 study in HealthyNew to Tanabe PharmaTanabe Pharma · NCT02953132 · 116 enrolled · Netherlands
- Jul 20, 2021Mineralys Therapeutics's first study: phase 2 study in Hypertension, RenalNew to Mineralys TherapeuticsMineralys Therapeutics · NCT05001945 · 200 enrolled · United States
- Aug 25, 2026MycoMedica Life Sciences PBC's first study: phase 1 study in Premenstrual Dysphoric DisorderNew to MycoMedica Life Sciences PBCMycoMedica Life Sciences PBC · NCT07818720 · 32 planned
Ahead
- Sep 2027Primary completion: phase 1 study in Premenstrual Dysphoric DisorderMycoMedica Life Sciences PBC · NCT07818720
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07818720Premenstrual Dysphoric Disorder | 1 | Not yet recruiting | MycoMedica Life Sciences PBC | Sep 2027 | 32 |
| NCT05001945Hypertension, Renal · United States | 2 | Completed | Mineralys Therapeutics | Sep 7, 2022 | 200 |
| NCT02953132Healthy · Netherlands | 1 | Completed | Tanabe Pharma | May 2017 | 116 |
How it is read
Names in the registry
- “MLS101 psilocybin”, 1 entry
- “MLS-101 (Part I)”, 1 entry
- “MLS-101 (Part II)”, 1 entry
- “MT-4129”, 1 entry
Conditions, from the studies’ own filings
- Premenstrual Dysphoric Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.